Get started
Author

Sophie Hallakou‐Bozec

Observed names: Hallakou-Bozec, Sophie, S Hallakou-Bozec, S. Hallakou-Bozec, SOPHIE HALLAKOU-BOZEC, Sophie Bozec, Sophie Hallakou-Bozec
Institution: Poxel SA (France)
ORCID: 0000-0001-8212-9518
Observed ORCID: 0000-0001-8212-9518
OpenAlex ID: A5067215954
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
2020 · Sophie Hallakou‐Bozec, Guillaume Vial, et al. · Diabetes Obesity and Metabolism · 214
PDF
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
2014 · Guillaume Vial, Marie-Agnès Chauvin, et al. · Diabetes · 207
Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
2016 · D Detaille, G Vial, et al. · Cell Death Discovery · 103
PDF
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
2023 · Stephen A. Harrison, Carole Thang, et al. · Journal of Hepatology · 101
PDF
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
2021 · Sophie Hallakou-Bozec, Micheline Kergoat, et al. · PLoS ONE · 99
PDF
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
2021 · Kenneth Cusi, Naim Alkhouri, et al. · The Lancet. Gastroenterology & hepatology · 82
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
2021 · Pascale Gluais‐Dagorn, Marc Foretz, et al. · Hepatology Communications · 78
PDF
Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
2016 · Rachel J. Perry, Rebecca L. Cardone, et al. · American Journal of Physiology-Endocrinology and Metabolism · 71
The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
2021 · Guillaume Vial, Frédéric Lamarche, et al. · Endocrinology Diabetes & Metabolism · 67
PDF
Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
2020 · Sophie Hallakou‐Bozec, Micheline Kergoat, et al. · Endocrinology Diabetes & Metabolism · 55
PDF
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
2021 · Pascale Fouqueray, Sebastien Bolze, et al. · Cell Reports Medicine · 54
Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
2020 · Marianne Lachaux, Matthieu Soulié, et al. · Endocrinology Diabetes & Metabolism · 52
PDF
Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
2021 · Vincent Jacques, Sébastien Bolze, et al. · Hepatology Communications · 51
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
2022 · Pierre Theurey, Guillaume Vial, et al. · Physiological Reports · 41
PDF
Engineering a pharmacologically superior form of leptin for the treatment of obesity
2005 · K.-M. Lo, J. Zhang, et al. · Protein Engineering Design and Selection · 34
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
2023 · Pascale Gluais Dagorn, Bjoern Buchholz, et al. · Kidney International · 32
PDF
Discovery and structure-guided drug design of inhibitors of 11β-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold
2009 · Franck Lepifre, Serge Christmann-Franck, et al. · Bioorganic & Medicinal Chemistry Letters · 28
Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
2022 · Pierre Theurey, Carole Thang, et al. · Endocrinology Diabetes & Metabolism · 26
Discovery and structure–activity relationships of pentanedioic acid diamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type I
2009 · Didier Roche, Denis Carniato, et al. · Bioorganic & Medicinal Chemistry Letters · 21
Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone— PXL065 —for X‐linked adrenoleukodystrophy
2022 · Pierre‐Axel Monternier, Jaspreet Singh, et al. · Journal of Inherited Metabolic Disease · 16
Imeglimin Protects INS-1 Cells and Human Islets against High Glucose– and High Fructose–Induced Cell Death by Inhibiting the Mitochondrial PTP Opening
2018 · SANDRINE LABLANCHE, EMILY TUBBS, et al. · Diabetes · 16
Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I
2012 · Eric Valeur, Serge Christmann-Franck, et al. · Bioorganic & Medicinal Chemistry Letters · 12
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy
2022 · Pierre-Axel Monternier, Parveen Parasar, et al. · Journal of Pharmacology and Experimental Therapeutics · 9
PDF
P2500Acute imeglimin treatment improves metabolic syndrome-related cardiac and coronary endothelial dysfunction in the zucker fa/fa rat
2018 · M Lachaux, M Souille, et al. · European Heart Journal · 5
Both short-and long-term treatment with the direct AMP kinase activator PXL770 improves cardiac function in ZSF-1 rats
2021 · Y Stephan, M Souille, et al. · European Heart Journal · 2
PDF
Works count: 33
Citation count: 1,479
H-index: 19
I10-index: 22
Year
Topic
Type